| JANCUSKOVA, T, R PLACHY, Jiří ŠTIKA, L ZEMANKOVA, DW HARDEKOPF, T LIEHR, N KOSYAKOVA, R CMEJLA, L ZEJSKOVA, T KOZAK, P ZAK, A ZAVRELOVA, P HAVLIKOVA, M KARAS, A JUNGE, C RAMEL and S PEKOVA. A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, vol. 37, No 10, p. 1363-1373. ISSN 0145-2126. Available from: https://dx.doi.org/10.1016/j.leukres.2013.06.009. |
Other formats:
BibTeX
LaTeX
RIS
@article{1429320,
author = {Jancuskova, T and Plachy, R and Štika, Jiří and Zemankova, L and Hardekopf, DW and Liehr, T and Kosyakova, N and Cmejla, R and Zejskova, L and Kozak, T and Zak, P and Zavrelova, A and Havlikova, P and Karas, M and Junge, A and Ramel, C and Pekova, S},
article_location = {OXFORD},
article_number = {10},
doi = {http://dx.doi.org/10.1016/j.leukres.2013.06.009},
keywords = {Acute leukemia; Minimal residual disease; Cytogenetics; Chromosome microdissection; Next-generation sequencing; Personalized medicine},
language = {eng},
issn = {0145-2126},
journal = {Leukemia Research},
title = {A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients},
volume = {37},
year = {2013}
}
TY - JOUR
ID - 1429320
AU - Jancuskova, T - Plachy, R - Štika, Jiří - Zemankova, L - Hardekopf, DW - Liehr, T - Kosyakova, N - Cmejla, R - Zejskova, L - Kozak, T - Zak, P - Zavrelova, A - Havlikova, P - Karas, M - Junge, A - Ramel, C - Pekova, S
PY - 2013
TI - A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients
JF - Leukemia Research
VL - 37
IS - 10
SP - 1363-1373
EP - 1363-1373
PB - PERGAMON-ELSEVIER SCIENCE LTD
SN - 01452126
KW - Acute leukemia
KW - Minimal residual disease
KW - Cytogenetics
KW - Chromosome microdissection
KW - Next-generation sequencing
KW - Personalized medicine
N2 - Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Common MRD targets include recurrent cytogenetic abnormalities and mutations in important hematological genes; unfortunately well-characterized targets are lacking in many AL patients. Here we demonstrate a technical approach for the identification and mapping of novel clone-specific chromosomal abnormalities down to the nucleotide level. We used molecular cytogenetics, chromosome microdissection, amplification of the microdissected material, and next-generation sequencing to develop PCR-based MRD assays based on unique breakpoint sequences. (C) 2013 Elsevier Ltd. All rights reserved.
ER -
JANCUSKOVA, T, R PLACHY, Jiří ŠTIKA, L ZEMANKOVA, DW HARDEKOPF, T LIEHR, N KOSYAKOVA, R CMEJLA, L ZEJSKOVA, T KOZAK, P ZAK, A ZAVRELOVA, P HAVLIKOVA, M KARAS, A JUNGE, C RAMEL and S PEKOVA. A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, vol.~37, No~10, p.~1363-1373. ISSN~0145-2126. Available from: https://dx.doi.org/10.1016/j.leukres.2013.06.009.
|
